The combination therapy also enhanced the presence and activation of interferon-γ (IFNγ)-expressing CD8 + cytotoxic T lymphocytes (CTLs) in tumor tissue, supporting tumor regression [110]. The gene discussed is IFNG; the disease is neoplasm.